Driving discovery
through clinical trials
The world’s most extensive program of in-human NMN research.
We are advancing a broad and diverse pipeline of small molecule therapies to address significant health- and lifespan associated conditions, and to develop treatment options for some of the most prevalent age-associated conditions and diseases.
Our pipeline is comprised of multiple preclinical and clinical-stage therapeutic candidates that have the potential to deliver optimal benefits while maintaining a strong safety profile.
| Study design | Expected completion date | |
|---|---|---|
| Skin anti-aging | 40 participants - 28 days - 5% nmn cream | Completed |
| Skin health | 60 participants - 56 days - 2% nmn cream | Completed |
| Physical capacity and muscle recovery | 150 participants - 38 days - placebo/NMN 250mg/NMN 500mg | Ongoing |
| Tolerance & NAD+ levels | 20 participants - 30 days - NMN 400mg | Completed |
| Pharmacokinetics | 24 participants - 30 days - NMN 400mg | Q4 2022 |
| Lipid and glucose management | 80 participants - 120 days - placebo/NMN 800m | Q3 2022 |
| Senior healthspan extension NMN vs NR | 200 participants - 360 days - placebo/NMN 750mg | Q4 2022 |
| Immune health | 200 participants - 120 days - placebo/NMN 600mg | Q3 2022 |
